First patient dosed with Transgene’s TG6002 in colorectal cancer with liver metastases

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 21, 2020 at 10:42 AM.

  1. #1 cafead, Feb 21, 2020 at 10:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the first patient has successfully received TG6002, via an intrahepatic artery (IHA) infusion, as a locoregional treatment for unresectable liver metastases from colorectal cancer (CRLM).

    article source
     
    Quote

Reply to Thread